New Brunswick, N.J., May 25, 2023 –Rutgers Cancer Institute of New Jersey and RWJBarnabas Health today announced that data from SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL), and two abstracts from the neoadjuvant I-SPY 2 trial evaluating oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer, have been selected as late-breaking presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held both in person in Chicago and online from June 2-6.
“We are thrilled to have physician-scientists from our health system participate in two innovative clinical trials selected for three late-breaking presentations at this year’s ASCO annual meeting, reinforcing our commitment to push the boundaries of science, provide patients with cutting-edge treatment options, and transform the way cancer is treated,” said Steven K. Libutti, MD, FACS, Director, Rutgers Cancer Institute of New Jersey and Senior Vice President, Oncology Services, RWJBarnabas Health. “As New Jersey’s only NCI-Designated Comprehensive Cancer Center, we strive to offer our patients comprehensive cancer care, including access to novel therapeutic advances and game-changing clinical trials that have the potential to save, extend and improve the quality of patients' lives, and reshape the future of cancer management.”
A total of 33 presentations and 9 publications have been accepted, highlighting research advances in several types of cancer, including lymphoma, pediatric, colorectal and breast cancer.
Highlights of additional accepted abstracts include the following:
- Initial findings of the phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (mCRC), found that TAS-102 with irinotecan plus bevacizumab is an effective second-line therapy for patients with mCRC.
- Findings from a cross-sectional, retrospective analysis that aimed to determine the association of receipt of treatment summaries, follow-up care instructions (including where to obtain “routine cancer check-ups”), and type of doctor providing survivorship care on breast cancer screening (BCS) and cervical cancer screening (CCS) in female cancer survivors. The analysis demonstrated that follow-up instructions, which are part of the survivorship plan, have the greatest association with BCS and CCS among cancer survivors, but despite this, about 25% of BCS and CCS-eligible cancer survivors did not receive them.
- Results from a phase Ib/II clinical trial evaluating the preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors, which demonstrated that tinengotinib monotherapy was well-tolerated and the pharmacokinetics results may support dose recommendation for subsequent trials. Additionally, researchers observed encouraging anticancer activity of tinengotinib monotherapy in patients with heavily pre-treated solid tumors, including PC, HR+/HER2- BC, TNBC and CCA.
The full list of presentations at the 2023 ASCO Annual Meeting follows:
|
Oral Presentations |
|
||
|
Abstract No. |
Title |
Presentation Date/Time |
Location |
|
Abstract 8006 |
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. |
Saturday, June 3, 2023, 3:15 p.m. CDT
|
Hall D2 & Live Stream |
|
Abstract 9501 |
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. |
Monday, June 5, 2023, 3:00 p.m. CDT |
Hall D1 & Live Stream
|
|
Abstract 1004 |
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC). |
Monday, June 5, 2023, 12:42 p.m. CDT |
Hall B1 & Live Stream |
|
Abstract 10008 |
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A. |
Sunday, June 4, 2023, 12:09 p.m. CDT |
S100a & Live Stream |
|
Poster Presentations |
|
||
|
Abstract No. |
Title |
Presentation Date/Time |
Location |
|
Abstract LBA612 |
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I SPY 2 TRIAL. |
Sunday, June 4, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract TPS3625 |
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract TPS5103 |
SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities. |
Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract TPS5109 |
HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer. |
Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract TPS5110 |
A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress. |
Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract TPS9594 |
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM). |
Saturday, June 3, 2023, 1:15 – 4:15 p.m. CDT |
Hall A & On Demand |
|
Abstract 532 |
A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer. |
Sunday, June 4, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 2561 |
Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA. |
Saturday, June 3, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 3085 |
Characterization of MCL-1 in patients with colorectal cancer (CRC): Expression, molecular profiles, and outcomes. |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 3531 |
Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type homologous recombination genes. |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 3590 |
Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO). |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 3622 |
Molecular profiling and characterization of the tumor immune microenvironment (TME) in appendiceal carcinoma (AC). |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 4108 |
Comprehensive profiling of clock genes expression in hepatocellular carcinoma (HCC). |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 4144 |
Correlation of comprehensive molecular mapping of pancreatic ductal adenocarcinoma with XPO1 mRNA expression levels to potential clinical targets. |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 4145 |
Clinical genomic implications of transcriptional subtypes in pancreatic cancer. |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 4150 |
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen. |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 4151 |
Molecular and clinical correlates of DSCR1 expression in pancreatic cancer (PDAC). |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 4167 |
The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study. |
Monday, June 5, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 9548 |
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis. |
Saturday, June 3, 2023, 1:15 – 4:15 p.m. CDT |
Hall A & On Demand |
|
Abstract 10628 |
Learned lessons from a US-wide outreach program to broaden enrollment to the PROMISE Registry, a prostate cancer genetic registry. |
Saturday, June 3, 2023, 1:15 – 4:15 p.m. CDT |
Hall A & On Demand |
|
Abstract 11018 |
Characterizing imposter syndrome among oncologists on social media. |
Sunday, June 4, 2023, 8:00 – 11:00 a.m. CDT |
Hall A & On Demand |
|
Abstract 12075 |
Survivorship care and breast and cervical cancer screening. |
Monday, June 5, 2023, 1:15 – 4:15 p.m. CDT |
Hall A & On Demand |
|
Poster Discussion Session |
|||
|
Abstract 2519 |
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. |
Saturday, June 3, 2023, 3:00 – 4:30 p.m. CDT |
S100bc & On Demand |
|
Abstract 3019 |
Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial. |
Saturday, June 3, 2023, 4:11 p.m. CDT |
S100bc & On Demand |
|
Abstract 4020 |
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome. |
Monday, June 5, 2023, 11:30 a.m. – 1:00 p.m. CDT |
Hall D2 & Live Stream |
|
Abstract 7515 |
Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744. |
Monday, June 5, 2023, 1:49 p.m. CDT |
E450 & On Demand |
|
Abstract Discussion 4 |
Aging in Survivors of Pediatric Cancer |
Monday, June 5, 2023, 5:36 p.m. CDT |
S504 & On Demand |
|
Abstract LBA520 |
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL. |
Sunday, June 4, 2023, 5:04 p.m. CDT
|
Hall B1 & Live Stream |
|
Plenary Session |
|||
|
Abstract LBA4 |
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). |
Sunday, June 4, 2023, 2:53 p.m. CDT |
Hall B1 & Live Stream
|
|
Publication Only |
|||
|
Session title |
Presentation title |
Presentation Date/Time |
Location |
|
Abstract e16073 |
Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial. |
N/A |
N/A |
|
Abstract e18723 |
Assessment of how differences in efficacy and toxicity change healthcare professionals’ views on presentation of treatment options. |
N/A |
N/A |
|
Abstract e15087 |
Safety and feasibility of the addition of a radiosensitizing methionine-restricted diet to radiation therapy. |
N/A |
N/A |
|
Abstract e17618 |
Comparing sentinel lymphadenectomy and complete lymphadenectomy among obese patients (BMI >30) undergoing minimally invasive hysterectomy for early-stage endometrial cancer: An ACS-NSQIP database study. |
N/A |
N/A |
|
Abstract e18605 |
Immediate inpatient toxicities associated with CAR T-cell therapy: Real world data from a national inpatient sample. |
N/A |
N/A |
|
Abstract e24088 |
Barriers to offering female fertility preservation to pediatric and young adult oncology patients: A national survey of pediatric hematology oncology providers in the United States and Canada. |
N/A |
N/A |
|
Abstract e12523 |
ctDNA detection before and during systemic therapy for inflammatory breast cancer. |
N/A |
N/A |
|
Abstract e16079 |
Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis. |
N/A |
N/A |
|
Abstract e19015 |
Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study. |
N/A |
N/A |
About Rutgers Cancer Institute of New Jersey
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting- edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.
For journalists – contact:
Krista Didzbalis
Media Relations Assistant
732-507-8307
krista.didzbalis@rutgers.edu
For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)